Kinetics of soluble TNF-receptors and soluble adhesion molecules ICAM-1, E-selectin and VCAM-1 under systemic rhTNFα therapy

European Journal of Clinical Investigation

Volumn 26, Issue 5, 1996, Pages 404-410

  Boehme, M W J ^a   Waldherr, R ^a   Kist, A ^a   Riedl, S ^a   Walter Kirst, R ^a   Kempeni, J ^b   Raeth, U ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Knoll AG   (Germany)

Author keywords

Endothelial cell; interleukin 6; soluble adhesion molecule; soluble tumour necrosis factor receptor; tumour necrosis factor

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOSTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

EID: 0030014936     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.151301.x     Document Type: Article

References (66)

1. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-2.
2. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986;320:584-8.
3. Sidhu RS, Bollon AP. Tumor necrosis factor activities and cancer therapy - a perspective. Pharmacol Ther 1993;57:79-128.
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
5. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: A common mediator. Annu Rev Biochem 1988;57:505-18.
6. Baglioni C. Mechanisms of cytotoxicity, cytolysis, and growth stimulation by TNF. In: Beutler B, ed. Tumor Necrosis Factor. New York: Raven Press, 1992: 425-38.
7. Wiedenmann B, Reichardt P, Räth U et al. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 1989;115:189-92.
8. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987;47:2986-89.
9. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988;6:344-50.
10. Creaven PJ, Brenner DE, Cowens JW et al. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 1989;23:186-91.
11. Moritz T, Niederle N, Baumann J. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol Immunother 1989;29:144-50.
12. Hersh EM, Metch BS, Muggia FM et al. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the Southwest Oncology Group experience. J Immunother 1991;10:426-31.
13. Feldmann ER, Creagan ET, Schaid DJ, Ahmann DL. Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma. Am J Clin Oncol 1992;15:256-9.
14. Aggarwal BB, Eessalu TE, Haas PE. Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature 1985;318:665-7.
15. Palladino MA, Shalaby MR, Kramer SM et al. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: Induction of tumor-specific immunity. J Immunol 1987;138:4023-32.
16. Schiller JH, Witt PL, Storer B et al. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer 1992;69:562-71.
17. Balkwill FR, Lee A, Aladam G et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferon. Cancer Res 1986;46:3990-3.
18. Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987;47:2403-6.
19. Nishimura T, Ohta S, Sato N, Togaski Y, Goto M, Hashimoto Y. Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice. Int J Cancer 1987;40:255-61.
20. Winkelhake JL, Stampfl S, Zimmerman RJ. Synergistic effects of combination therapy with human recombinant interleukin 2 and tumor necrosis factor in murine tumor models. Cancer Res 1987;47:3948-53.
21. Norioka K, Borden EC, Auerbach R. Inhibitory effects of cytokines on vascular endothelial cells: Synergistic interactions among interferon-α, tumor necrosis factor-α, and interleukin-1. J Immunother 1992;12:13-18.
22. Negrier MS, Fourreau CN, Palmer PA et al. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer. J Immunother 1992;11:93-102.
23. Abbruzzese JL, Levin B, Ajani JA et al. Phase I trial of recombinant human-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res 1989;49:4057-61.
24. Demetri GD, Spriggs DR, Sherman ML, Arthur KA, Imamura K, Kufe DW. A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: Effects of combination cytokine administration in vivo. J Clin Oncol 1989;7:1545-53.
25. Jones AL, O'Brien MER, Lorentzos A et al. A randomised phase II study of carmustine alone or in combination with tumor necrosis factor in patients with advanced melanoma. Cancer Chemother Pharmacol 1992;30:73-6.
26. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune F. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and Melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
27. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990;70:427-51.
28. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986;163:1363-75.
29. Clauss M, Ryan J, Stern D. Modulation of endothelial cell hemostatic properties by TNF: Insights into the role of endothelium in the host response to inflammatory stimuli. In: Beutler B, ed. Tumor Necrosis Factor. New York: Raven Press 1992: 49-64.
30. Sato N, Goto T, Haranaka K et al. Actions of tumor necrosis factor on cultured vascular epithelial cells: morphologic modulation, growth inhibition and cytotoxicity. J Natl Cancer Inst 1986;76:1113-7.
31. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989;74:165-72.
32. Kist A, Ho AD, Räth U et al. Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood 1988;72:344-8.
33. Robaye B, Mosselmans R, Fiers WW. Dumont JE, Galant P. Tumor necrosis factor induces apoptosis (programmed all death) in normal endothelial cells in vitro. Am J Pathol 1991;138:447-53.
34. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 1988;141:2629-34.
35. Bevilaqua MP, Pober JS, Mendrick DL, Cotran RS, Grimbrone MA. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987;84:9238-42.
36. Pober JS, Bevilaqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 1986;136:1680-7.
37. Carlos TM, Schwartz BR, Kovach NL et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 1990;76:965-70.
38. Carlos T, Kovach N, Schwartz B et al. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: Endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 1991;77:2266-71.
39. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321-31.
40. Bevilaqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804.
41. Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules. E-selectin, ICAM-1, and VCAM-1: Pathological significance. Ann NY Acad Sci 1992;667:324-31.
42. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-31.
43. Nawroth P, Handley D, Matsueda G et al. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988;168:637-47.
44. Cronstein BN, Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum 1993;36:147-57.
45. Mackay CR, Imhof BA. Cell adhesion in the immune system. Immunol Today 1993;14:99-102.
46. Shimizu Y, Newman W, Gopal TV et al. Four molecular pathways of T cell adhesion to endothelial cells: Roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions. J Cell Biol 1991;113:1203-12.
47. Lobb RR, Chi-Rosso G, Leone DR et al. Expression and functional characterization of a soluble form of endothelial leukocyte adhesion molecule 1. J Immunol 1991;147:124-9.
48. Pigott R, Dillon LP, Hemingway IH, Gearing AJH. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992:187:584-9.
49. Newman W, Beall LD, Carson CW et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993;150:644-54.
50. Leeuwenberg JFM, Smeets EF, Neefjes JJ et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-9.
51. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-12.
52. Seth R, Raymond RD, Makgoba MW. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 1991;338:83-4.
53. Hviid L, Theander TG, Elhassan IM, Jensen JB. Increased plasma levels of soluble ICAM-1 and ELAM-1 (E-selectin) during acute Plasmodium falciparum malaria. Immunol Lett 1993;36:51-8.
54. Kling E, Bieg S, Boehme M, Scherbaum WA. Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. Clin Invest 1993;71:299-304.
55. Boehme MWJ, Nawroth PP, Kling E et al. Serum Thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994;37:572-7.
56. Boehme MWJ, Werle E, Kommerell B, Raeth U. Serum levels of adhesion molecules and thrombomodulin as indicators of vascular injury in severe Plasmodium falciparum malaria. Clin Invest 1994;72:598-603.
57. Gerlach H, Lieberman H, Bach R, Godman G, Brett J, Stern D. Enhanced responsiveness of endothelium in the growing motile state to tumor necrosis factor/cachectin. J Exp Med 1989;170:913-31.
58. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992;13:151-3.
59. Thoma B, Grell M, Pfizenmaier K, Scheurich P. Identification of a 60 kDa tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med 1990;172:1019-23.
60. Seckinger P, Isaaz S, Dayer J-M. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988;167:1511-16.
61. Peetre C, Thysell H, Grubb A, Olsson I. A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol 1988;41:414-19.
62. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990;265:1531-6.
63. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kD TNF receptor signals cell death. Cell 1993;74:845-53.
64. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumor necrosis factor-α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 1993;177:1277-86.
65. Shalaby MR, Waage A, Aarden L, Espevik T. Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol 1989;53:488-98.
66. Brouckaert P, Spriggs DR, Demetri G, Kule DW, Fiers W. Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon-α. J Exp Med 1989:169:2257-62.